Production of antibody and development of enzyme-linked immunosorbent assay for therapeutic drug monitoring of eravacycline

Galvidis, I.A.; Moshcheva, A.G.; Surovoy, Y.A.; Sobolev, P.D.; Sharipov, V.R.; Sidorov, N.G.; Tsarenko, S.V.; Burkin, M.A.

Авторы: Galvidis Inna A., Moshcheva Anastasia G., Surovoy Yury A., Sobolev Pavel D., Sharipov Vitaly R., Sidorov Nikita G., Tsarenko Sergei V., Burkin Maksim A.
Журнал: Journal of Pharmaceutical and Biomedical Analysis
Том: 242
Год издания: 2024
Издательство: Elsevier BV
Местоположение издательства: Netherlands
Номер статьи: 116033
DOI: 10.1016/j.jpba.2024.116033
Аннотация: Eravacycline (ERC) was approved for clinical use in 2018. It is more potent than other tetracyclines and can overcome resistance, making it an attractive option for combating multidrug-resistant bacterial infections. Intensive pharmacokinetic (PK) studies are currently being conducted to ensure the effectiveness and safety of ERC in various groups of patients, including those undergoing extracorporeal therapies. This study is the first attempt to develop a simple, efficient, and high-throughput immunoassay for quantifying ERC in human or animal serum. BSA-ERC conjugate as immunogen elicited antibody production in rabbits. Monitoring of the immune response and comparison of homologous and heterologous coating antigens allowed selection of immunoreagents and development of an assay that was selective for ERC possessing sensitivity (IC50), dynamic range (IC20-IC80) and detection limit equal to 3.3 ng/mL, 0.27–54 ng/mL and 0.09 ng/mL, respectively. The developed ELISA showed acceptable recovery of ERC (85–105 %) from rabbit and human serum in the clinically relevant concentration range of 0.1–3.0 mg/L. The method was used to quantify serum ERC concentration in the pilot PK study in Soviet chinchilla rabbits. The results were confirmed by HPLC-MS/MS.
Добавил в систему: Гальвидис Инна Александровна

	ИСТИНА	Войти в систему Регистрация
	ИСТИНА ЦЭМИ РАН
	Главная Поиск Статистика О проекте Помощь

ИСТИНА

ИСТИНА ЦЭМИ РАН

Production of antibody and development of enzyme-linked immunosorbent assay for therapeutic drug monitoring of eravacyclineстатья

Прикрепленные файлы